US Patent 10047160 Anti-EGFRvIII antibodies and uses thereof
Patent 10047160 was granted and assigned to Regeneron Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+547 characters)
Article
Patent abstract
The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100471600
Date of Patent
August 14, 2018
0Patent Application Number
151706280
Date Filed
June 1, 2016
0Patent Citations Received
Patent Primary Examiner
Edits on 11 Apr, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100471600
Date of Patent
August 14, 2018
0Patent Application Number
151706280
Date Filed
June 1, 2016
0Patent Primary Examiner
Edits on 21 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10047160 Anti-EGFRvIII antibodies and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10047160
Date of patent
August 14, 2018
Patent application number
15170628
Date Filed
June 1, 2016
Patent primary examiner
Find more entities like US Patent 10047160 Anti-EGFRvIII antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
